KALA BIO Company Description

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States.

The company’s product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.

Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases.

The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023.

KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

KALA BIO, Inc.

Country	United States
Founded	2009
Industry	Medical - Pharmaceuticals
Sector	Healthcare
Employees	43
CEO	Mark Iwicki

Contact Details

Address: 1167 Massachusetts Avenue Arlington, Delaware 02476 United States
Phone	781 996 5252
Website	kalarx.com

Stock Details

Ticker Symbol	0JQ2
Exchange	London Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US4831192020
SIC Code	2836

Key Executives

Name	Position
Mark Iwicki	Chief Executive Officer
Mary Reumuth	Chief Financial Officer
Todd Bazemore	Chief Operating Officer
Jill Steier	Head of Investor Relations